1. Acceptance Your access to and use of this Site is subject to the following terms and conditions and all applicable laws. By accessing and browsing this Site you accept, without limitation or qualification, these Terms and...

For more than 25 years, we have been at the forefront of driving scientific advancements and improving clinical practice in collaboration with the global breast cancer community. With one of the most diverse breast cancer pipelines and the largest number of compounds in development, Novartis leads the industry in discovery of new therapies and combinations.

Over the past decade, our research has supported the evolution of treatment approaches for patients living with mutation-driven types of lung cancer. We remain focused on the global lung cancer community through ongoing studies as well as the exploration of investigational compounds that target genomic biomarkers.

Melanoma is the most serious type of skin cancer, and in many cases is caused by damage to the DNA in skin cells; more than half of melanoma cases are caused by these genetic changes. Through research, investigational studies and advocacy, Novartis brings attention and support to those battling advanced melanoma.

We are passionate about our work for patients with life-threatening blood cancers and serious non-cancer blood disorders. Together with the medical community, we are reimagining hematology.